Project Grant R21AI183320

Award Date 3/21/25
Completion Date 2/28/27
Dollars Obligated $257K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award of $1,517,519 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program) supports research to identify the upstream drivers of type I interferon production in systemic lupus erythematosus (SLE). The project, titled "Upstream Drivers of Type I Interferons in Lupus", focuses on understanding the molecular mechanisms by which innate immune cells, such as neutrophils and monocytes, and skin cells...
This $2,902,477 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a study exploring remission and relapse in patients with systemic lupus erythematosus (SLE). The research aims to analyze immune cell profiles and brain function in SLE patients in long-term clinical remission to understand patient heterogeneity, identify predictors of sustained remission or flare, and reveal novel states of immune...
This $1,622,956 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the role of IgA autoantibodies in the development of systemic lupus erythematosus (SLE). The primary awardee, Benaroya Research Institute at Virginia Mason, will use this 5-year grant to determine the mechanisms by which IgA autoantibodies enhance plasmacytoid dendritic cell...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $895,140 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Progentec Diagnostics Inc., a minority-owned small business located in Oklahoma City, OK. The purpose of this late-stage research project is to validate two innovative laboratory tests, the Lupus Flare Risk Index (L-FRI) and the Lupus Disease Activity Index (L-DAI), which are designed to detect immune dysregulation...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $173,556 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Yale University. The grant supports a 5-year career development program for a physician-scientist to study the role of retroelements in systemic lupus erythematosus (SLE). The key objectives are to: 1) Delineate gene, retroelement, and inflammatory cytokine expression patterns in the blood and skin of SLE patients; 2)...
This $375,100 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support a research study focused on understanding the role of cyclic GMP-AMP synthase (cGAS) activation and nucleic-acid-dependent phase separation in regulating immune responses associated with systemic lupus erythematosus (SLE). The study, led by researchers at The Johns...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $793,093 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Oklahoma Medical Research Foundation (OMRF) to define the regulatory landscape of systemic lupus erythematosus (SLE) with cardiovascular disease (CVD) comorbidity. The research project aims to systematically study thousands of SLE-associated genetic variants to identify causal regulatory elements, target genes, and cell...
The University of Massachusetts Medical School was awarded a $494,929 Project Grant from the National Institute of Allergy and Infectious Diseases to study the role of Toll-like receptors, type II interferon and type III interferon in a murine model of autoinflammation. The grant will support research exploring the effector mechanisms responsible for inducing and regulating cutaneous lupus using genetically modified mice with discriminating mutations. Specifically, the researchers will use...
This $300,000 Project Grant was awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to the Regents of the University of Minnesota. The funding supports research to define the roles of the LYN kinase isoforms, LYNA and LYNB, in immune signaling and their contributions to the development of systemic lupus erythematosus (SLE). The research aims to: 1) elucidate how the LYN isoforms differentially regulate ITAM, TLR, and estrogen receptor...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the CFDA Program "Arthritis, Musculoskeletal and Skin Diseases Research", provides $300,000 in funding to the Beckman Research Institute of the City of Hope to conduct research on eradicating pathogenic plasma cells and their precursors in Systemic Lupus Erythematosus (SLE). The research aims to determine the effect of knocking down the long isoform of the prolactin...

This federal Project Grant award, numbered R21AI183320, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The total funding amount is $256,808.00 for the project period from March 21, 2025 to February 28, 2027.

The goal of this research project is to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The key focus areas include: 1) expanding the analysis of altered mRNA splicing in SLE neutrophils and understanding its relation to factors like sex, age, disease activity, and type I interferons; 2) exploring the consequences of altered mRNA splicing in SLE, such as the production of novel, potentially antigenic peptides; and 3) elucidating the underlying mechanisms driving the dysregulation of mRNA splicing in SLE. This research aims to clarify whether the production of neo-autoantigens is a feature of SLE and introduce new avenues for therapeutic development.

Generated 4/8/25, 4:32 AM